The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders

International Journal of Geriatric Psychiatry

Volumn 17, Issue 11, 2002, Pages 1012-1017

  Mamo, David C ^a   Sweet, Robert A ^b,c   Chengappa, K N Roy ^b   Reddy, Ravinder R ^b,c   Jeste, Dilip V ^d  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Depot neuroleptic; Dosing; Management; Psychotic disorders; Schizophrenia; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPHENAZINE DECANOATE; HALOPERIDOL DECANOATE; NEUROLEPTIC AGENT;

ADULT; AGE; AGED; AGING; AMBULATORY CARE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE SEVERITY; DRUG DOSE REDUCTION; ELDERLY CARE; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PROSPECTIVE STUDY; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TARDIVE DYSKINESIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUPHENAZINE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; PRODRUGS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 0036848587     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.740     Document Type: Article

References (23)

1. Bezchlibnyk-Butler KZ, Jeffries JJ. 1995. Clinical Handbook of Psychotropic Drugs. Hans Huber: Toronto.
2. Casey DE. 1995. Neuroleptic-induced acute extrapyramidal syndromes and tardive dyskinesia. In. Schizophrenia, Hirsh SR, Weinberger DR (eds). Blackwell Science Ltd: Oxford; 546-564.
3. Crane GE, Smeets RA. 1974. Tardive dyskinesia and drug therapy in geriatric patients. Arch Gen Psychiatry 30: 341-343.
4. Expert Consensus Group: 1999. Expert consensus treatment guidelines for schizophrenia: a guide for patients and families. J Clin Psychiatry 60(Suppl. 11): 73-80.
5. Guy W (ed.). 1976. ECDEU Assessment Manual for Psychopharmacology, Revised, DHEW Pub. No. (ADM) 76-338. National Institute of Mental Health: Rockville, MD.
6. Harris MJ, Heaton RK, Schulz A, Bailey A, Patterson TL. 1997. Neuroleptic dose reduction in older psychotic patients. Schizophrenia Res 27: 241-248.
7. Hirsch SR, Barnes TRE. 1995. The clinical treatment of schizophrenia with antipsychotic medication. In Schizophrenia, Hirsch SR, Weinberger DR (eds). Blackwell Science Ltd: Oxford; 443-468.
8. Jeste DV, Lacro JP, Gilbert LG, Kline J, Kline N. 1993. Treatment of late-life schizophrenia with neuroleptics. Schizophrenia Bull 19(4): 817-830.
9. Jeste DV, Caligiuri MP, Paulsen JS, et al. 1995a. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 52: 756-765.
10. Jeste DV, Claigiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ. 1995b. Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 52: 756-765.
11. Kane JM, Rifkin A, Woerner M, et al. 1993. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry 40(8): 893-896.
12. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. 1986. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 22: 254-258.
13. Kotchev R, Alken RG, McKay G, Katzarov T. 1996. Absolute bioavailability of oral immediate and slow release fluphenazine in healthy volunteers. Eur J Clinical Pharmacol 51(2): 183-187.
14. Lacro JP, Kuczenski R, Roznoski M, Warren KA, Harris MJ, Jeste DV. 1996. Serum Haloperidol Levels in Older Psychotic Patients. Am J Geriatr Psychiatry 4:229-236.
15. Leon J, Canuso C, White AO, Simpson GM. 1994. A pilot effort to determine benztropine equivalents of anticholinergic medications. Hosp Comm Psychiatry 45(6): 606-607.
16. Mamo DC, Sweet RA, Keshavan MS. 1999. Managing antipsychotic-induced Parkinsonism. Drug Safety 20(3): 269-275.
17. Morselli PL, Bianchetti G, Tedeschi G, Braithwaite RA. 1981. Haloperidol: clinical pharmacokinetics and significance of therapeutic blood monitoring. In Therapeutic Drug Monitoring, Rickens and Marks (eds). Churchill Livingstone: Edinburgh; 298-306.
18. Pollock BG, Mulsant BH. 1995. Antipsychotics in older patients: a safety perspective. Drugs Aging 6: 312-323.
19. Prudo R, Blum HM. 1987. Five-year outcome and prognosis in schizophrenia: a report from the London Field Research Centre of the International Pilot Study of Schizophrenia. Br J Psychiatry 150: 345-354.
20. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ. 1993. Dosaging patterns in schizophrenia with depot, oral, and combined neuroleptic therapy. Can J Psychiatry 38(3): 159-161.
21. Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry 39(4): 486-487.
22. Sweet RA, Pollock BG. 1998. New atypical antipsychotics: experience and utility in the elderly. Drugs Aging 12(2): 115-127.
23. Sweet RA, Mulsant BH, Gupta B, Rifai AH, Pasternak RE, McEachran A, Zubenko GS. 1995. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 52: 478-486.